Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
CD19-BCMA Targeted CAR-T(Tangdu Hospital) in Lambert-Eaton Myasthenic Syndrome: NCT06371040 Clinical Landscape Report 2026
9 min read
CD19-BCMA Targeted CAR-T(Tangdu Hospital) in Lambert-Eaton Myasthenic Syndrome: NCT06371040 Clinical Landscape Report 2026
28 September 2026
NCT06371040 clinical landscape for Lambert-Eaton Myasthenic Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
Read →
LTSE-2578 in Idiopathic Pulmonary Fibrosis: ACTRN12624000535572 Clinical Landscape Report 2026
9 min read
LTSE-2578 in Idiopathic Pulmonary Fibrosis: ACTRN12624000535572 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000535572 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Neostigmine Methylsulfate in Myasthenia Gravis: ACTRN12624000545561 Clinical Landscape Report 2026
9 min read
Neostigmine Methylsulfate in Myasthenia Gravis: ACTRN12624000545561 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000545561 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Efgartigimod/Hyaluronidase in Myasthenia Gravis: NCT06392386 Clinical Landscape Report 2026
9 min read
Efgartigimod/Hyaluronidase in Myasthenia Gravis: NCT06392386 Clinical Landscape Report 2026
28 September 2026
NCT06392386 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Busulfan in Anemia, Sickle Cell: NCT06399107 Clinical Landscape Report 2026
9 min read
Busulfan in Anemia, Sickle Cell: NCT06399107 Clinical Landscape Report 2026
28 September 2026
NCT06399107 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Prednisolone Acetate in Myasthenia Gravis: TCTR20240515008 Clinical Landscape Report 2026
9 min read
Prednisolone Acetate in Myasthenia Gravis: TCTR20240515008 Clinical Landscape Report 2026
28 September 2026
TCTR20240515008 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Zilucoplan in Myasthenia Gravis: NCT06435312 Clinical Landscape Report 2026
9 min read
Zilucoplan in Myasthenia Gravis: NCT06435312 Clinical Landscape Report 2026
28 September 2026
NCT06435312 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Aspirin in Obstetric Labor, Premature: NCT06417411 Clinical Landscape Report 2026
9 min read
Aspirin in Obstetric Labor, Premature: NCT06417411 Clinical Landscape Report 2026
28 September 2026
NCT06417411 clinical landscape for Obstetric Labor, Premature: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Taladegib in Idiopathic Pulmonary Fibrosis: NCT06422884 Clinical Landscape Report 2026
9 min read
Taladegib in Idiopathic Pulmonary Fibrosis: NCT06422884 Clinical Landscape Report 2026
28 September 2026
NCT06422884 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Bromophenoxyazole Propanoic Acid in Myasthenia Gravis: NCT06414954 Clinical Landscape Report 2026
9 min read
Bromophenoxyazole Propanoic Acid in Myasthenia Gravis: NCT06414954 Clinical Landscape Report 2026
28 September 2026
NCT06414954 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
GC-012F in Myasthenia Gravis: NCT06419166 Clinical Landscape Report 2026
9 min read
GC-012F in Myasthenia Gravis: NCT06419166 Clinical Landscape Report 2026
28 September 2026
NCT06419166 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Motixafortide in Semicircular Canal Dehiscence: NCT06442761 Clinical Landscape Report 2026
9 min read
Motixafortide in Semicircular Canal Dehiscence: NCT06442761 Clinical Landscape Report 2026
28 September 2026
NCT06442761 clinical landscape for Semicircular Canal Dehiscence: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →